



DAFTAR PUSTAKA

- Aloizou, A.M. *et al.* (2020) ‘The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?’, *Toxicology Reports*, 7(November), pp. 1514–1530. Available at: <https://doi.org/10.1016/j.toxrep.2020.11.001>.
- Amining, M.M., Hartanto, R.A. and Ghazaly, R. (2024) *Hubungan Kadar D-Dimer Terhadap Kesintasan Pasien Glioblastoma*. Universitas Gadjah Mada.
- Bautista-Becerril, B. *et al.* (2023) ‘High Expression Levels of miR-21-5p in Younger Hospitalized COVID-19 Patients Are Associated with Mortality and Critical Disease’, *International Journal of Molecular Sciences*, 24(12), pp. 1–16. Available at: <https://doi.org/10.3390/ijms241210112>.
- Bautista-Sánchez, D. *et al.* (2020) ‘The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics’, *Molecular Therapy Nucleic Acids*, 20(22), pp. 409–420. Available at: <https://doi.org/10.1016/j.omtn.2020.03.003>.
- Christodoulidis, G. *et al.* (2025) ‘Status quo of hypercoagulation as a prognostic indicator following neoadjuvant immunochemotherapy in locally advanced gastric cancer’, *World journal of gastrointestinal oncology*, 17(9), pp. 1–10. Available at: <https://doi.org/10.4251/wjgo.v17.i9.106868>.
- Cote, D.J. and Dawood, H.Y. (2016) ‘Venous Thromboembolism in Patients with High-Grade Glioma Venous Thromboembolism in Patients with High-Grade Glioma’, (November 2021).
- D’Asti, E., Fang, Y. and Rak, J. (2014) ‘Brain Neoplasms and Coagulation—Lessons from Heterogeneity’, *Rambam Maimonides Medical Journal*, 5(4), p. e0030. Available at: <https://doi.org/10.5041/rmmj.10164>.
- Dewdney, B. *et al.* (2023) ‘From signalling pathways to targeted therapies: unravelling glioblastoma ’ s secrets and harnessing two decades of progress’, (August). Available at: <https://doi.org/10.1038/s41392-023-01637-8>.
- Du, X. *et al.* (2019) ‘MiR-21 induces endothelial progenitor cells proliferation and angiogenesis via targeting FASLG and is a potential prognostic marker in deep venous thrombosis’, *Journal of Translational Medicine*, 17(1), pp. 1–14. Available at: <https://doi.org/10.1186/s12967-019-2015-z>.



- Edwin, N.C. *et al.* (2016) 'Recurrent venous thromboembolism in glioblastoma', *Thrombosis Research*, 137, pp. 184–188. Available at: <https://doi.org/10.1016/j.thromres.2015.11.027>.
- Eisele, A. *et al.* (2022) 'Venous thromboembolic events in glioblastoma patients: An epidemiological study', *European Journal of Neurology*, 29(8), pp. 2386–2397. Available at: <https://doi.org/10.1111/ene.15404>.
- Esemen, Y. *et al.* (2022) 'Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review', *International Journal of Molecular Sciences*, 23(5). Available at: <https://doi.org/10.3390/ijms23052607>.
- Fang, C. *et al.* (2024) 'Advances in microRNA regulation of deep vein thrombosis through venous vascular endothelial cells (Review)', *Molecular Medicine Reports*, 29(6), pp. 1–9. Available at: <https://doi.org/10.3892/mmr.2024.13220>.
- Gabriely, G. *et al.* (2008) 'MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators', *Molecular and Cellular Biology*, 28(17), pp. 5369–5380. Available at: <https://doi.org/10.1128/mcb.00479-08>.
- Hanif, F. *et al.* (2017) 'Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment', *Asian Pacific Journal of Cancer Prevention*, 18(1), pp. 3–9. Available at: <https://doi.org/10.22034/APJCP.2017.18.1.3>.
- He, L. and Zhou, Y. (2022) 'Evaluation of increased microRNA-21 in the serum of patients with cardia cancer', (9).
- Hoke, M. *et al.* (2011) 'Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study', *Wiener Klinische Wochenschrift*, 123(7–8), pp. 199–203. Available at: <https://doi.org/10.1007/s00508-011-1556-9>.
- Kapteijn, M.Y. *et al.* (2024) 'Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications', *Thrombosis and Haemostasis* [Preprint]. Available at: <https://doi.org/10.1055/s-0044-1789592>.
- Kim, M. *et al.* (2021) 'Neuro-Oncology Advances in adults', 3(September), pp. 1–13.
- Koudriavtseva, T. *et al.* (2021) 'Neutrophil-to-lymphocyte ratio, factor viii and



- antithrombin iii: Inflammatory-clotting biomarkers in glioma’, *EXCLI Journal*, 20, pp. 1152–1169. Available at: <https://doi.org/10.17179/excli2021-3831>.
- Laghari, A.A. *et al.* (2024) ‘Clinical and Molecular Characterization of Glioma Patients: miR-21 Expression as a Prognostic Biomarker in Tissue and Serum’, *bioRxiv : the preprint server for biology* [Preprint].
- Lan, Z., Li, X. and Zhang, X. (2024) ‘Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers’, *International Journal of Molecular Sciences*, 25(5). Available at: <https://doi.org/10.3390/ijms25053040>.
- Li, C. *et al.* (2016) ‘Prognostic role of microRNA-21 expression in gliomas: a meta-analysis’, *Journal of Neuro-Oncology*, 130(1), pp. 11–17. Available at: <https://doi.org/10.1007/s11060-016-2233-7>.
- Li, K. *et al.* (2018) ‘Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973-2014’, *Cancer Medicine*, 7(10), pp. 5281–5290. Available at: <https://doi.org/10.1002/cam4.1757>.
- Lim-Fat, M.J. *et al.* (2019) ‘Letter: When less is more: Dexamethasone dosing for brain tumors’, *Clinical Neurosurgery*, 85(3), pp. E607–E608. Available at: <https://doi.org/10.1093/neuros/nyz186>.
- Liu, Y. *et al.* (2014) ‘A feedback regulatory loop between HIF-1 α and miR-21 in response to hypoxia in cardiomyocytes’, *FEBS Letters*, 588(17), pp. 3137–3146. Available at: <https://doi.org/10.1016/j.febslet.2014.05.067>.
- Louis, D.N. *et al.* (2016) ‘The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary’, *Acta Neuropathologica*, 131(6), pp. 803–820. Available at: <https://doi.org/10.1007/s00401-016-1545-1>.
- MacFarlane, L.-A. and R. Murphy, P. (2010) ‘MicroRNA: Biogenesis, Function and Role in Cancer’, *Current Genomics*, 11(7), pp. 537–561. Available at: <https://doi.org/10.2174/138920210793175895>.
- Makowska, M., Smolarz, B. and Romanowicz, H. (2023) ‘microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)—Recent Literature Review’, *International Journal of Molecular Sciences*, 24(4), pp. 1–23. Available at: <https://doi.org/10.3390/ijms24043521>.
- Mandoj, C., Tomao, L. and Conti, L. (2019) ‘Coagulation in Brain Tumors: Biological Basis and Clinical Implications’, *Frontiers in Neurology*, 10(March),



- pp. 1–7. Available at: <https://doi.org/10.3389/fneur.2019.00181>.
- Muster, V. and Gary, T. (2021) ‘Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk’, *Cells*, 215(1), p. 5. Available at: <https://doi.org/10.1038/sj.bdj.2013.638>.
- Nakajima, N. *et al.* (2018) ‘BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity’, *Brain Pathology*, 28(5), pp. 663–673. Available at: <https://doi.org/10.1111/bpa.12572>.
- Nath, S.K. *et al.* (2019) ‘Central Nervous System Cancers’, *Absolute Clinical Radiation Oncology Review*, pp. 83–131. Available at: https://doi.org/10.1007/978-3-319-96809-4_3.
- Navone, S.E. *et al.* (2019) ‘Significance and Prognostic Value of The Coagulation Profile in Patients with Glioblastoma: Implications for Personalized Therapy’, *World Neurosurgery*, 121, pp. e621–e629. Available at: <https://doi.org/10.1016/j.wneu.2018.09.177>.
- Nizamutdinov, D. *et al.* (2018) ‘Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma’, *World Neurosurgery*, 109, pp. e67–e74. Available at: <https://doi.org/10.1016/j.wneu.2017.09.104>.
- Ohgaki, H. and Kleihues, P. (2013) ‘The definition of primary and secondary glioblastoma’, *Clinical Cancer Research*, 19(4), pp. 764–772. Available at: <https://doi.org/10.1158/1078-0432.CCR-12-3002>.
- Oronsky, B. *et al.* (2021) ‘A Review of Newly Diagnosed Glioblastoma’, *Frontiers in Oncology*, 10(February), pp. 1–10. Available at: <https://doi.org/10.3389/fonc.2020.574012>.
- Ostrom, Q.T. *et al.* (2020) ‘CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017’, *Neuro-Oncology*, 22(Supplement_1), pp. IV1–IV96. Available at: <https://doi.org/10.1093/neuonc/noaa200>.
- Posch, F. *et al.* (2020) ‘Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study’, *Journal of Thrombosis and Haemostasis*, 18(6), pp. 1348–1356. Available at:



<https://doi.org/10.1111/jth.14774>.

Reihanian, Z. *et al.* (2024) 'Impact of Age and Gender on Survival of Glioblastoma Multiforme Patients: A Multicenter Retrospective Study', *Cancer Reports*, 7(11), pp. 1–9. Available at: <https://doi.org/10.1002/cnr2.70050>.

Roth, P. *et al.* (2021) 'Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up †', *Annals of Oncology*, 32(2), pp. 171–182. Available at: <https://doi.org/10.1016/j.annonc.2020.11.003>.

Sanjaya, A. (2023) 'microRNA: Sebuah panduan pemula untuk klinisi dan peneliti', *Journal of Medicine and Health*, 5(1), pp. 80–94. Available at: <https://doi.org/10.28932/jmh.v5i1.3540>.

Senst, B. *et al.* (2023) *Hypercoagulability*, *StatPearls*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK538251/> (Accessed: 8 May 2025).

Shi, R. *et al.* (2015) 'Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients', *Oncotarget*, 6(29), pp. 26971–26981. Available at: <https://doi.org/10.18632/oncotarget.4699>.

Smith, E.R. *et al.* (2008) 'Urinary biomarkers predict brain tumor presence and response to therapy', *Clinical Cancer Research*, 14(8), pp. 2378–2386. Available at: <https://doi.org/10.1158/1078-0432.CCR-07-1253>.

Stupp, R. *et al.* (2017) 'Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial', *JAMA - Journal of the American Medical Association*, 318(23), pp. 2306–2316. Available at: <https://doi.org/10.1001/jama.2017.18718>.

Tian, M. *et al.* (2018) 'Impact of gender on the survival of patients with glioblastoma', *Bioscience Reports*, 38(6), pp. 1–9. Available at: <https://doi.org/10.1042/BSR20180752>.

Villanacci, V. *et al.* (2019) 'Clinical manifestations and gastrointestinal pathology in 40 patients with autoimmune enteropathy', *Clinical Immunology*, 207(May), pp. 10–17. Available at: <https://doi.org/10.1016/j.clim.2019.07.001>.

Wang, W. *et al.* (2018) 'Human cancer cells suppress behaviors of endothelial



- progenitor cells through miR-21 targeting IL6R', *Microvascular Research*, 120(287), pp. 21–28. Available at: <https://doi.org/10.1016/j.mvr.2018.05.007>.
- Wang, X. *et al.* (2019) 'Association of recurrent venous thromboembolism and circulating microRNAs', *Clinical Epigenetics*, 11(1). Available at: <https://doi.org/10.1186/s13148-019-0627-z>.
- Weinberg, I. *et al.* (2021) 'Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels', *Thrombosis Update*, 2(November 2020). Available at: <https://doi.org/10.1016/j.tru.2020.100029>.
- Wen, P.Y. *et al.* (2010) 'Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group', *Journal of Clinical Oncology*, 28(11), pp. 1963–1972. Available at: <https://doi.org/10.1200/JCO.2009.26.3541>.
- Wen, P.Y. *et al.* (2020) 'Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions', *Neuro-Oncology*, 22(8), pp. 1073–1113. Available at: <https://doi.org/10.1093/neuonc/noaa106>.
- Wu, L. *et al.* (2013) 'MicroRNA-21 expression is associated with overall survival in patients with glioma', *Diagnostic Pathology*, 8(1), pp. 1–5. Available at: <https://doi.org/10.1186/1746-1596-8-200>.
- Xu, L. *et al.* (2022) 'Combination of Circulating miR-125a-5p, miR-223-3p and D-dimer as a Novel Biomarker for Deep Vein Thrombosis', *The American Journal of the Medical Sciences*, 364(5), pp. 601–611. Available at: <https://doi.org/https://doi.org/10.1016/j.amjms.2022.04.033>.
- Young, R.M. *et al.* (2015) 'Current trends in the surgical management and treatment of adult glioblastoma', *Annals of Translational Medicine*, 3(9), pp. 1–15. Available at: <https://doi.org/10.3978/j.issn.2305-5839.2015.05.10>.
- Zhang, Y. *et al.* (2018) 'The p53 pathway in glioblastoma', *Cancers*, 10(9). Available at: <https://doi.org/10.3390/cancers10090297>.